Skip to main content

Advertisement

Table 1 Baseline characteristics of subjects in the 2 groups

From: Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes

Clinical characteristics The group A (n = 29) The group B (n = 27)
Age (years) 56.8 ± 12.3 56.3 ± 12.4
Sex (Male/Female) 15/14 13/14
Body weight (kg) 66.2 ± 16.3 67.2 ± 15.9
BMI (kg/m2) 25.2 ± 3.6 25.4 ± 3.7
Waist Circumference (cm) 93.55 ± 10.5 93.46 ± 10.4
duration of diabetes (years) 15.6 ± 5.7 15.4 ± 6.2
Hypertention (+/−) 22/7 21/6
Retinopathy(NDR/SDR/PDR) 2/17/10 2/16/9
Nephropathy(Normo-/micro-/macroalbuminuria) 6/14/9 5/14/8
CVD(−/+) 5/24 5/22
α-glucosidase inhibitors(-/ +) 2/27 1/26
Metformin (−/ +) 13/16 14/13
Duration of insulin treatment (years) 9.6 ± 3.4 9.4 ± 3.5
Total insulin dose (unit/day) 68.6 ± 14.6 66.8 ± 13.9
Frequency of insulin injection (2-/3−/−4 times /d) 17/8/4 16/7/4
HbA1c (%) 9.3 ± 1.5 9.4 ± 1.4
FBG (mmol/L) 11.4 ± 2.4 11.3 ± 2.6
P2BG (mmol/L) 16.8 ± 4.4 17.0 ± 4.5
Triglyceride (mmol/L) 3.26 ± 1.14 3.28 ± 1.16
Total Cholesterol (mmol/L) 6.23 ± 1.41 6.19 ± 1.51
HDL-Cholesterol (mmol/L) 1.04 ± 0.23 1.12 ± 0.21
LDL-Cholesterol (mmol/L) 4.13 ± 1.01 4.20 ± 1.02
Serum C peptide (ng/ml) 1.06 ± 0.68 1.06 ± 0.70
HMW adiponectin (μg/ml) 3.12 ± 1.56 3.22 ± 1.54
  1. Normally distributed data expressed as mean ± standard deviation and non-normally distributed data expressed as median or as numbers and percentages. Non-normally distributed data were log-transformed for use with parametric statistics. BMI: body mass index; NDR: no diabetic retinopathy; SDR: simple diabetic retinopathy; PDR: proliferative diabetic retinopathy; CVD: cardiovascular disease; HbA1c: Glycosylated hemoglobin; FBG: fasting blood glucose; P2BG: 2-hour postprandial blood glucose; LDL: low-density lipoprotein; HMW adiponectin: high-molecular weight adiponectin.